B-lymphocytes are essential for an efficient immune response against a variety of path-ogens. A large fraction of hematologic malignancies are of B-cell origin, suggesting that the development and activation of B cells must be tightly regulated. In recent years, differentially expressed non-coding RNAs have been identified in mantle cell lymphoma (MCL) tumor samples as opposed to their naive, normal B-cell compartment. These aberrantly expressed molecules, specif-ically microRNAs (miRNAs), circular RNAs (circRNAs) and long non-coding RNAs (lncRNAs), have a role in cellular growth and survival pathways in various biological models. Here, we pro-vide an overview of current knowledge on the role of non-coding RNAs and their relevant targets in B-cell development, activation and malignant transformation, summarizing the current understanding of the role of aberrant expression of non-coding RNAs in MCL pathobiology with per-spectives for clinical use.
CITATION STYLE
Kersy, O., Salmon-Divon, M., Shpilberg, O., & Hershkovitz-Rokah, O. (2021, September 1). Non-coding RNAs in normal B-cell development and in mantle cell lymphoma: From molecular mechanism to biomarker and therapeutic agent potential. International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms22179490
Mendeley helps you to discover research relevant for your work.